Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stalevo vs Levodopa/Carbidopa in Parkinson's Disease (SEWOP)
NCT00125567Phase 4Completed
- Sponsor
- Orion Corporation
- Start
- Aug 2005
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial of entacapone in Parkinson's disease (PD) (2 arms), sponsored by Orion Corporation. Primary endpoint: Time until a patient requires changes in antiparkinsonian therapy due to inadequately controlled parkinsonian symptoms at 2 years. Started Aug 2005; status: completed.
02
Drugs
entacapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00125567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125567.